Abstract:This review provides an overview of relevant aspects of retinoid physiology and molecular biology, and summarizes the current status of clinical investigations on the use of retinoid for the treatment of malignancies. The mechanism underlying the anticarcinogenic activity of retinoids appears to be associated with the ability of retinoids to modulate the growth and induce differentiation, and apoptosis of normal, premalignant, and malignant cellsin vitro andin vivo. Retinoid effects seem to be resulted from changes in gene expression mediated via specific nuclear receptors (termed retinoic acid receptors, RAR-α, -β and -γ). Chromosome translocations play an important role in APL pathogenesis. In the classical translocation, RAR a gene is fused with PML gene to form PML-RAR a chimeric gene, which is expressed in over 95% of the APL patients with t (15; 17) (q22; q21). Therefore, PML-RAR a fusion gene is the molecular marker of APL. ATRA can induce relocalization of the PML and restore the normal structure of POD. Furthermore, it could cause a degradation of PML-RAR α. In addition to the very high clinical response rate for APL patients treated with ATRA, clinical responses have been observed for patients with myelodysplastic syndrome, cutaneous T-cell lymphoma and skin cancers. Applications of retinoids are reviewed in different malignancies: including skin cancer, head and neck carcinoma, neuroblastoma, lung cancer, breast cancer, prostate cancer, bladder cancer and ovarian cancerin vivo andin vitro studies. The results indicate that retinoids are potentially useful agents for cancer prevention. RA combined with IFNs or RA combined with G-CSF has synergistic effect in inducing differentiation of cell growth. From current clinical results at least four leads are expected to impact on clinical development of retinoids in future: (1) development of retinoid receptor-selective agents; (2) investigation on cross-talk among members of the steroid superfamily; (3) strategies for attaining sufficient tissue levels of retinoids; (4) combined use with other differentiation or chemotherapeutic agents.

Structure–Activity Relationships and Therapeutic Applications of Retinoids in View of Potential Benefits from Drug Repurposing Process

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Retinoic Acid and Its Derivatives in Skin

Retinoids and Their Applications in Clinic

Retinoic Acid and Its Derivatives in Dermatological Disorders

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

Synthetic Retinoids as Potential Therapeutics in Prostate Cancer-An Update of the Last Decade of Research: A Review

Molecular Interactions of Selective Agonists and Antagonists with the Retinoic Acid Receptor γ

Inspired by vitamin A for anti-ageing: Searching for plant-derived functional retinoid analogues

Topical retinoids: Novel derivatives, nano lipid-based carriers, and combinations to improve chemical instability and skin irritation

Molecular Mechanisms of Retinoic Acid Action

Re-emergence of topical retinol in dermatology

Endoplasmic reticulum stress as a target for retinoids in cancer treatment

An overview about Therapeutic uses, clinical efficacy, safety and classes of Retinoids and its efficacy for Treatment of skin aging

Retinoids: Concepts for Separation of Desirable and Undesirable Effects in the Treatment or Prevention of Cancer

Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments

A Structure-based Approach to Retinoid X Receptor-α Inhibition

Topical Treatment for Retinal Degenerative Pathologies: A Systematic Review

Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant Metabolism of Retinoids

Clinical review: topical retinoids

Therapeutic Potential and Pharmaceutical Development of a Multitargeted Flavonoid Phloretin